|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2002
|
|
gptkbp:approvedBy
|
gptkb:United_States
|
|
gptkbp:associatedWith
|
gptkb:Granix
gptkb:Zarxio
gptkb:filgrastim
|
|
gptkbp:ATCCode
|
L03AA13
|
|
gptkbp:biosimilar
|
yes
|
|
gptkbp:CASNumber
|
208265-92-3
|
|
gptkbp:drugClass
|
colony-stimulating factor
|
|
gptkbp:form
|
pre-filled syringe
on-body injector
|
|
gptkbp:genericName
|
gptkb:pegfilgrastim
|
|
gptkbp:halfLife
|
15-80 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Neulasta
|
|
gptkbp:indication
|
reduce infection risk in cancer patients
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Amgen
|
|
gptkbp:mechanismOfAction
|
stimulates production of neutrophils
|
|
gptkbp:patentExpired
|
2015 (US)
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescribes
|
patients receiving myelosuppressive chemotherapy
|
|
gptkbp:PubChem_CID
|
none
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
gptkb:acute_respiratory_distress_syndrome
bone pain
allergic reactions
splenic rupture
|
|
gptkbp:UNII
|
Q1J8A4J3XZ
|
|
gptkbp:usedFor
|
chemotherapy-induced neutropenia
prevention of neutropenia
|
|
gptkbp:bfsParent
|
gptkb:Amgen
|
|
gptkbp:bfsLayer
|
6
|